KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) Return on Equity (2016 - 2025)

BeOne Medicines (ONC) has disclosed Return on Equity for 10 consecutive years, with 0.11% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 30.0% to 0.11% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.11%, a 30.0% increase, with the full-year FY2025 number at 0.12%, up 31.0% from a year prior.
  • Return on Equity was 0.11% for Q4 2025 at BeOne Medicines, up from 0.02% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.11% in Q4 2025 to a low of 0.44% in Q3 2022.
  • A 5-year average of 0.26% and a median of 0.28% in 2021 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: grew 30bps in 2021, then dropped -13bps in 2022.
  • BeOne Medicines' Return on Equity stood at 0.31% in 2021, then tumbled by -42bps to 0.43% in 2022, then surged by 44bps to 0.24% in 2023, then grew by 21bps to 0.19% in 2024, then skyrocketed by 157bps to 0.11% in 2025.
  • Per Business Quant, the three most recent readings for ONC's Return on Equity are 0.11% (Q4 2025), 0.02% (Q3 2025), and 0.05% (Q2 2025).